International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 146-152
RESULTS OF 77-04 CHEMOTHERAPY REGIMEN IN HIGH GRADE NON-HODGKIN LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE
AYHAN DÖNMEZ1, SEÇKİN ÇAĞIRGAN1, MURAT TOMBULOĞLU1
Ege Üniversitesi Tıp Fakültesi Hematoloji BD, İZMİR
Keywords: non-hodgkin lymphoma, high grade, chemotherapy
After the demonstration of efficiency of high dose chemotherapy regimens in pediatric Burkitt and lymphoblastic lymphomas, adult patients were also begun to be treated with similar approaches. The 77-04 protocol reported in 1984 by Magrath et al has been administered to 17 adult patients between November 1993 - December 2001 in our hematology department. The patients tolerated the treatment considerably well. The most frequent side effects were myelosupression and mucositis. No mortality related to chemotherapy was observed. Complete remission was achieved in 13 patients (76.4 %) and partial remission in one patient. 3 patients were considered as refractory to the treatment. Median follow-up is 107.5 months in all patients. Disease free survival at 112 months was found to be 48.6 %. Six patients including four stage IV lymphoblastic lymphomas died with progressive disease. These results suggest that 77-04 chemotherapy regimen is highly efficient in high grade lymphomas; however for achieving long disease free survival in stage IV lymphoblastic lymphomas more aggressive treatment modalities are necessary.
AYHAN DÖNMEZ1, SEÇKİN ÇAĞIRGAN1, MURAT TOMBULOĞLU1
Ege Üniversitesi Tıp Fakültesi Hematoloji BD, İZMİR
Keywords: non-hodgkin lymphoma, high grade, chemotherapy
After the demonstration of efficiency of high dose chemotherapy regimens in pediatric Burkitt and lymphoblastic lymphomas, adult patients were also begun to be treated with similar approaches. The 77-04 protocol reported in 1984 by Magrath et al has been administered to 17 adult patients between November 1993 - December 2001 in our hematology department. The patients tolerated the treatment considerably well. The most frequent side effects were myelosupression and mucositis. No mortality related to chemotherapy was observed. Complete remission was achieved in 13 patients (76.4 %) and partial remission in one patient. 3 patients were considered as refractory to the treatment. Median follow-up is 107.5 months in all patients. Disease free survival at 112 months was found to be 48.6 %. Six patients including four stage IV lymphoblastic lymphomas died with progressive disease. These results suggest that 77-04 chemotherapy regimen is highly efficient in high grade lymphomas; however for achieving long disease free survival in stage IV lymphoblastic lymphomas more aggressive treatment modalities are necessary.